TAR-200 Monotherapy Has 82.8% Complete Response Rate in BCG-Unresponsive HR-NMIBC
Updated findings from SunRISe-1 also showed that all but 1 responder achieved complete response within 12 weeks of treatment with the targeted gemcitabine delivery system.